Skip to main content

Artificial Intelligence-driven, Decentralized Production for Advanced Therapies in the Hospital

Objective

AIDPATH (Artificial Intelligence-driven, Decentralized Production for Advanced Thera-pies in the Hospital) is a high-energy EU consortium, dedicated to enable and to augment the next-generation of personalized medicine at EU hospitals through the use of AI tech-nology. The exemplary embodiment of gene-engineered immune cells in AIDPATH will be T cells expressing a synthetic chimeric antigen receptor (CAR-T). These cells are already a revolutionary novel treatment in hematology and oncology, and will also be useful for treating infections and autoimmune diseases. Conventional CAR-T therapy is complicated by complex logistics from centralized manufacturing facilities, inflexible manufacturing and clinical use schemes that disregard patient and cell characteristics, thus limiting patient access and therapeutic outcome.
AIDPATH will apply top-notch AI technology to integrate patient-specific data and biomarkers in CAR-T therapy, and apply flexible manufacturing schemes to obtain CAR-T cell products with optimal fitness and anti-tumor potency. AI technology will be applied in pre- and in-process controls to reduce cost and hospital resource utilization and to augment patient access. AIDPATH will establish a role model that integrates the hospital in a smart manner, incorporating aspects of logistics, capacity planning, data management and cybersecurity by design. The project is designed to enable smart ‘bedside’ provision of personalized treatments and to accomplish end-to-end automation of hospital-based CAR-T manufacture. A key deliverable in AIDPATH will be an integrated cyberphysical infrastructure for rapid dissemination of the ‘smart CAR-T manufacturing and clinical use’ concept to hospitals throughout the EU.
AIDPATH brings together a world-class consortium to address these challenges, consisting of key opinion leaders in science and translational medicine, innovative SMEs and commercial partners, patient advocates, policy makers and regulatory experts.

Field of science

  • /medical and health sciences/basic medicine/immunology/autoimmune diseases
  • /medical and health sciences/clinical medicine/hematology

Call for proposal

H2020-DT-2020-1
See other projects for this call

Funding Scheme

IA - Innovation action

Coordinator

FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
Address
Hansastrasse 27C
80686 Munchen
Germany
Activity type
Research Organisations
EU contribution
€ 2 957 166,25

Participants (11)

UNIVERSITY COLLEGE LONDON
United Kingdom
EU contribution
€ 1 086 371,25
Address
Gower Street
WC1E 6BT London
Activity type
Higher or Secondary Education Establishments
IDRYMA TECHNOLOGIAS KAI EREVNAS
Greece
EU contribution
€ 788 750
Address
N Plastira Str 100
70013 Irakleio
Activity type
Research Organisations
SZAMITASTECHNIKAI ES AUTOMATIZALASI KUTATOINTEZET
Hungary
EU contribution
€ 697 500
Address
Kende Utca 13-17
1111 Budapest
Activity type
Research Organisations
UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Germany
EU contribution
€ 1 507 500
Address
Josef-schneider-strasse 2
97080 Wurzburg
Activity type
Higher or Secondary Education Establishments
AGLARIS CELL SL
Spain
EU contribution
€ 698 250
Address
Calle Santiago Grisolia N 2
28760 Tres Cantos
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
FUJIFILM EUROPE BV
Netherlands
EU contribution
€ 174 999,13
Address
Oudenstraat 1
5047 TK Tilburg
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
FUNDACIO CLINIC PER A LA RECERCA BIOMEDICA
Spain
EU contribution
€ 250 000
Address
Carrer Rossello 149
08036 Barcelona
Activity type
Research Organisations
IRIS TECHNOLOGY SOLUTIONS, SOCIEDAD LIMITADA
Spain
EU contribution
€ 256 375
Address
Calle Velazquez, No 94 Primera Planta
28006 Madrid
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
RED ALERT LABS
France
EU contribution
€ 298 112,50
Address
71 Rue Carnot
94700 Maisons-alfort
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
PANAXEA BV
Netherlands
EU contribution
€ 348 140,63
Address
Science Park 400 Matrix Ii Unit 3.1
1098 XH Amsterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ORTEC OPTIMIZATION TECHNOLOGY BV
Netherlands
EU contribution
€ 797 826,75
Address
Houtsingel 5
2719EA Zoetermeer
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)